title: Erythema multiforme to amoxicillin with concurrent infection by Epstein-Barr virus.
abstract: BACKGROUND
  The incidence of rashes following the intake of aminopenicillins during an acute episode of infectious mononucleosis is high, but severe cutaneous reactions as erythema multiforme or Stevens-Johnson syndrome are rare manifestations in childhood.
  
  
  METHODS
  We report the case of a 7 year old girl that developed a generalized purpuric rash with target shaped areas, 9 days after starting treatment with amoxicillin-clavulanic acid. Laboratory investigation revealed a significant increase of Epstein Barr virus (EBV) specific IgM antibody. After skin biopse she was diagnosed as erythema multiforme syndrome. Prick, intradermal and patch tests were performed with penicilloylpolylysine, minor determinant mixture, benzylpenicillin, ampicillin, amoxicillin, cefazoline and cefotaxime, the 24 hours reading was positive for aminopenicillins. Patch tests were also positive only for aminopenicillins, other betalactams were negative.
  
  
  CONCLUSIONS
  The interaction between an infectious agent (EBV) and amoxicillin could precipitate the severe skin reaction. Patch test and delayed intradermal reading with amoxicilllin were an useful tool for the diagnosis of the etiological agent in this reaction. The negative response to other beta-lactams, suggests that the aminobenzyl group of the side chain of amoxicillin plays a predominant role in this reaction.
authors.affiliation: Allergy Seccion, Hospital General de Alicante, Alicante, Spain. gonzalez_pur@gva.es
authors.forename: Purificación
authors.initials: P
authors.lastname: González-Delgado
authors.forename: Mar
authors.initials: M
authors.lastname: Blanes
authors.forename: Víctor
authors.initials: V
authors.lastname: Soriano
authors.forename: Dulce
authors.initials: D
authors.lastname: Montoro
authors.forename: Carlos
authors.initials: C
authors.lastname: Loeda
authors.forename: Enrique
authors.initials: E
authors.lastname: Niveiro
mesh_terms: D000658:Amoxicillin / Q000009:adverse effects*; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000008:administration & dosage / Q000627:therapeutic use; D001706:Biopsy; D002648:Child; D003875:Drug Eruptions / Q000209:etiology*; D020031:Epstein-Barr Virus Infections / Q000150:complications*; D004892:Erythema Multiforme / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007111:Immunity, Cellular; D007075:Immunoglobulin M / Q000097:blood / Q000276:immunology; D007428:Intradermal Tests; D010328:Patch Tests; D010397:Penicillanic Acid / Q000009:adverse effects / Q000031:analogs & derivatives; D010406:Penicillins / Q000009:adverse effects; D012882:Skin Tests; D047090:beta-Lactams / Q000009:adverse effects
chemical_list: D007075:Immunoglobulin M; D010406:Penicillins; D047090:beta-Lactams; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin; D010397:Penicillanic Acid; C004408:aminopenicillanic acid